ClinicalTrials.gg
CompletedNCT06334419Updated Sep 30, 2026Results posted

Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

A Phase 2 interventional study of Gaboxadol and Placebo in Fragile X Syndrome, sponsored by Craig Erickson. Completed at 1 site in United States. Open to male participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Craig Erickson · Phase 2, Interventional, and Basic science

How we know

Updated Sep 30, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Fragile X Syndrome with a site in United States — 11 open to participants now, 16 under way, 2 of them phase 3. Fragile X Syndrome · United States.

Enrollment
62nd of 68
10 · median 60
Started
2024
with 1 other
Phase 2
28 of 82
2 open now
Registered
75th of 82
by date

Among the 82 studies in Fragile X Syndrome with a site in United States, this one is the 62nd largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2024, is one of 28 in phase 2, and was the 75th registered.

Fragile X Syndrome

115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.

Browse Fragile X Syndrome studies →

Open to participants now

11 of the 82 studies in Fragile X Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 40 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Fragile X Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded fashion.

03

Conditions studied

  • Fragile X Syndrome

Browse trials for

Keywords

  • Fragile X
  • Fragile X Syndrome
  • FXS
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject consents to participate, or if they are not their own legal guardian, offers assent supported by legally authorized representative consent
  2. Subject is willing and able to comply with the study procedures as specified in the protocol and to comply with the study drug administration. Caregiver also commits to the study requirements prior to any study-related procedures
  3. Subject and caregiver are both able to understand the spoken national language clearly and caregiver can read and write to complete study assessments
  4. Males age 18 to 40 years (inclusive)
  5. Has FXS with molecular genetic confirmation of the full FMR1 mutation (>200 cysteine-guanine-guanine [CGG] repeats). May have been confirmed historically or at Screening
  6. Is in general good health as deemed by the Investigator, determined by physical examination, medical history, and laboratory tests
  7. If receiving serotonin-selective reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or serotonin antagonist and reuptake inhibitor (SARI), is on a stable, well-tolerated dose for the previous 3 months with no further changes anticipated
  8. Is not sexually active or can confirm at least one form of

Exclusion criteria

Exclusion Criteria:

  1. Any chronic major medical comorbid condition deemed by the Investigator as presenting added risk to the subject, including but not limited to, hypertension, kidney disease, or liver disease
  2. Diagnosed with diabetes (Type 1 or II) or receiving any anti-diabetic medication
  3. Unstable seizure disorder, defined by any seizure within 6 months prior to baseline visit and/or a change in any anti-convulsant drug dosing in the 60 days prior to study consent
  4. Changes in psychotropic or anti-convulsant (where taken for reasons other than seizure control) drug treatment within 30 days prior to Screening
  5. Significant changes in any educational, behavioral, and/or dietary interventions the month prior to Screening
  6. Planned initiation of new, or modification of ongoing, interventions during the study
  7. Unable or unwilling to take oral medication (whole capsule, despite assistance with a spoonful of applesauce, yoghurt, or equivalent liquid food)
  8. Consumption of liver enzyme inducers or inhibitors including and not limited to foods, medicines, herbal remedies and supplements three days prior to any Visit. Foods or beverages containing /5 inhibitors (e.g., grapefruit, pomegranate, pomelo, and star fruit) should be avoided before taking study medication and for up to 1 hour post dose throughout the study
  9. Has abnormal baseline laboratory assessments including, but not limited to, (ALT) or aspartate aminotransferase (AST) or total >1.5 × the (ULN), serum creatinine >1.5 x ULN or other laboratory abnormality
  10. Has a clinically significant heart rate or blood pressure (BP) at Screening as judged by the Investigator
  11. Has received an drug in any prior clinical study within 30 days or 5 half-lives (whichever is longer) prior to Screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Placebo in lab, Gaboxadol in home, Gaboxadol in lab, Placebo in home

    Individuals in this condition received Placebo in lab, Gaboxadol in home, Gaboxadol in lab, then Placebo in home.

    Drug: Gaboxadol · Drug: Placebo

  • Experimental
    Gaboxadol in lab, Gaboxadol in home, Placebo in lab, Placebo in home

    Individuals in this condition received Gaboxadol in lab, Gaboxadol in home, Placebo in lab, then Placebo in home.

    Drug: Gaboxadol · Drug: Placebo

  • Experimental
    Placebo in lab, Placebo in home, Gaboxadol in lab, Gaboxadol in home

    Individuals in this condition received Placebo in lab, Placebo in home, Gaboxadol in lab, then Gaboxadol in home.

    Drug: Gaboxadol · Drug: Placebo

  • Experimental
    Gaboxadol in lab, Placebo in home, Placebo in lab, Gaboxadol in home

    Individuals in this condition received Gaboxadol in lab, Placebo in home, Placebo in lab, then Gaboxadol in home.

    Drug: Gaboxadol · Drug: Placebo

Interventions

  • Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

  • DrugPlacebo

    Two placebo capsules

06

What researchers measure

Primary outcomes

  1. Target Engagement of Gaboxadol Treatment on EEG Power

    Changes in EEG recordings with gaboxadol treatment (assessed at pre-dose, 60 minutes post-dose, average response across home and lab reported). compared with pre-dose on resting theta, alpha and gamma band absolute power. Absolute power measures reflect the median power averaged across 129 electrodes in μV²/Hz. Means are presented using the average of home and lab values.

    Time frame: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

  2. Target Engagement of Gaboxadol Treatment on Auditory Chirp

    Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on brain response to auditory chirp stimuli), as measured by intertrial phase coherence (ITC). Means are presented using the average of home and lab values.

    Time frame: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Secondary outcomes

  1. To Investigate the Feasibility of Home Research Visits and Procedures in Adult Males With FXS

    Quality and test-retest reliability of assessments performed at home compared with the hospital setting. This includes blood testing for Fragile X messenger ribonucleoprotein (FMRP: range of 0-40 picomolar) and eye-tracking of eye gaze to eye regions when viewing faces (range of value from 0 percent to 100 percent; higher values are associated with a neurotypical phenotype).

    Time frame: Pre-dose, 60 minutes post-dose

  2. To Investigate the Feasibility of High Density EEG Recording at Home in Adult Males With FXS

    This endpoint examined the reliability of pre-dose resting-state EEG absolute power estimates between in-lab and in-home assessments using intraclass correlation (ICC). ICCs were calculated separately for 129 electrodes using absolute power estimates (μV²/Hz). The reported ICC represents the mean ICC across electrodes, with the standard deviation reflecting variability in ICC values across electrodes. whole-head, pre-dose resting state EEG power estimates from data collected in-lab vs in-home using intraclass correlation (ICC).

    Time frame: Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42

  3. To Potentially Explore the Pharmacokinetics of Gaboxadol Treatment in Single-dose Trial Design

    PK profile (the level of gaboxadol in human plasma) will be obtained at 60 +/- 10 minutes post-dose only).

    Time frame: Sixty minutes post-dose on 4 study visits, up to day 42

  4. To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments

    Changes in cognitive and neuropsychological assessment measures with gaboxadol treatment (RBANS List Learning). During the RBANS List Learning subtests, participants listen to a list of 10 words and repeat back as many as they can remember four times, for a maximum score of 40. Change scores were calculated by subtracting pre-dose words remembered from post-dose words remembered, with positive scores meaning an improvement in memory.

    Time frame: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

  5. To Investigate the Effect of Gaboxadol Treatment on Eye Tracking Assessments

    Change in eye tracking outcomes (60-90 minutes post-dose compared to pre-dose on percent viewing of social versus geometric scene

    Time frame: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

  6. To Investigate the Effect of Gaboxadol Treatment on Clinician-rated Measures

    Score on the Clinical Global Impressions - Improvement (CGI-I) scale, a clinician rating scale with "1" anchored to "very much improved" and "7" anchored to "very much worse."

    Time frame: Post-dose on 4 study visits, up to day 42

  7. To Determine Whether FMRP Levels Predict Treatment Response

    Relationship between FMRP (Fragile X messenger ribonucleoprotein) level and degree of change (baseline/screen to post-dose) across measures

    Time frame: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

07

Results

Posted Sep 30, 2026

Participant flow

First intervention (1 day)
Participant flow — First intervention (1 day)
MilestonePlacebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home
Started2332
Completed2332
Not completed0000
Washout period (14 days)
Participant flow — Washout period (14 days)
MilestonePlacebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home
Started2332
Completed2332
Not completed0000
Second intervention (1 day)
Participant flow — Second intervention (1 day)
MilestonePlacebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home
Started2332
Completed2332
Not completed0000
Washout period (14 days)
Participant flow — Washout period (14 days)
MilestonePlacebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home
Started2332
Completed2332
Not completed0000
Third intervention (1 day)
Participant flow — Third intervention (1 day)
MilestonePlacebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home
Started2332
Completed2332
Not completed0000
Washout period (14 days)
Participant flow — Washout period (14 days)
MilestonePlacebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home
Started2332
Completed2332
Not completed0000
Fourth intervention (1 day)
Participant flow — Fourth intervention (1 day)
MilestonePlacebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in Home
Started2332
Completed2332
Not completed0000

Outcome measures

PrimaryTarget Engagement of Gaboxadol Treatment on EEG Power

Changes in EEG recordings with gaboxadol treatment (assessed at pre-dose, 60 minutes post-dose, average response across home and lab reported). compared with pre-dose on resting theta, alpha and gamma band absolute power. Absolute power measures reflect the median power averaged across 129 electrodes in μV²/Hz. Means are presented using the average of home and lab values.

Time frame:
Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Reported as:
Mean · μV²/Hz
Target Engagement of Gaboxadol Treatment on EEG Power
μV²/HzGaboxadolPlacebo
Theta pre-dose2.19 ± 1.852.07 ± 2.09
Theta post-dose4.06 ± 2.882.07 ± 2.06
Alpha pre-dose-1.01 ± 1.88-1.32 ± 1.84
Alpha post-dose-0.18 ± 2.02-1.10 ± 1.99
Gamma pre-dose-8.78 ± 2.73-8.81 ± 2.41
Gamma post-dose-8.95 ± 2.81-8.87 ± 2.32
Statistical analysis
  • Gaboxadol vs Placebo · Mixed Models Analysis · p = .0008
  • Gaboxadol vs Placebo · Mixed Models Analysis · p = .008
  • Gaboxadol vs Placebo · Mixed Models Analysis · p = .82
SecondaryTo Investigate the Feasibility of Home Research Visits and Procedures in Adult Males With FXS

Quality and test-retest reliability of assessments performed at home compared with the hospital setting. This includes blood testing for Fragile X messenger ribonucleoprotein (FMRP: range of 0-40 picomolar) and eye-tracking of eye gaze to eye regions when viewing faces (range of value from 0 percent to 100 percent; higher values are associated with a neurotypical phenotype).

Time frame:
Pre-dose, 60 minutes post-dose

No measurements were reported for this outcome.

SecondaryTo Investigate the Feasibility of High Density EEG Recording at Home in Adult Males With FXS

This endpoint examined the reliability of pre-dose resting-state EEG absolute power estimates between in-lab and in-home assessments using intraclass correlation (ICC). ICCs were calculated separately for 129 electrodes using absolute power estimates (μV²/Hz). The reported ICC represents the mean ICC across electrodes, with the standard deviation reflecting variability in ICC values across electrodes. whole-head, pre-dose resting state EEG power estimates from data collected in-lab vs in-home using intraclass correlation (ICC).

Time frame:
Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42
Reported as:
Mean · correlation coefficient
To Investigate the Feasibility of High Density EEG Recording at Home in Adult Males With FXS
correlation coefficientAll Study Participants
Delta ICC0.77 ± .11
Theta ICC0.83 ± 0.10
Alpha ICC0.86 ± .10
Beta ICC.75 ± .17
Gamma ICC.67 ± .14
SecondaryTo Potentially Explore the Pharmacokinetics of Gaboxadol Treatment in Single-dose Trial Design

PK profile (the level of gaboxadol in human plasma) will be obtained at 60 +/- 10 minutes post-dose only).

Time frame:
Sixty minutes post-dose on 4 study visits, up to day 42

Results for this outcome have not been posted.

SecondaryTo Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments

Changes in cognitive and neuropsychological assessment measures with gaboxadol treatment (RBANS List Learning). During the RBANS List Learning subtests, participants listen to a list of 10 words and repeat back as many as they can remember four times, for a maximum score of 40. Change scores were calculated by subtracting pre-dose words remembered from post-dose words remembered, with positive scores meaning an improvement in memory.

Time frame:
Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Reported as:
Least squares mean · Change in words remembered
To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments
Change in words rememberedGaboxadolPlacebo
To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments2.38 ± 1.46-0.5 ± 1.46
SecondaryTo Investigate the Effect of Gaboxadol Treatment on Eye Tracking Assessments

Change in eye tracking outcomes (60-90 minutes post-dose compared to pre-dose on percent viewing of social versus geometric scene

Time frame:
Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Results for this outcome have not been posted.

SecondaryTo Investigate the Effect of Gaboxadol Treatment on Clinician-rated Measures

Score on the Clinical Global Impressions - Improvement (CGI-I) scale, a clinician rating scale with "1" anchored to "very much improved" and "7" anchored to "very much worse."

Time frame:
Post-dose on 4 study visits, up to day 42
Reported as:
Count of units · sessions
To Investigate the Effect of Gaboxadol Treatment on Clinician-rated Measures
sessionsGaboxadolPlacebo
Post dose: CGI rating of 100
Post dose: CGI rating of 200
Post dose: CGI rating of 320
Post dose: CGI rating of 41820
Post dose: CGI rating of 500
Post dose: CGI rating of 600
Post dose: CGI rating of 700
SecondaryTo Determine Whether FMRP Levels Predict Treatment Response

Relationship between FMRP (Fragile X messenger ribonucleoprotein) level and degree of change (baseline/screen to post-dose) across measures

Time frame:
Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Results for this outcome have not been posted.

PrimaryTarget Engagement of Gaboxadol Treatment on Auditory Chirp

Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on brain response to auditory chirp stimuli), as measured by intertrial phase coherence (ITC). Means are presented using the average of home and lab values.

Time frame:
Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Reported as:
Mean · unitless
Target Engagement of Gaboxadol Treatment on Auditory Chirp
unitlessGaboxadolPlacebo
Chirp ITC pre-dose42.8 ± 22.743.1 ± 19.7
Chirp ITC post-dose38.4 ± 19.641.2 ± 18.8
Statistical analysis
  • Gaboxadol vs Placebo · t-test, 1 sided · p = .76
  • Gaboxadol vs Placebo · t-test, 1 sided · p = .52

Adverse events

Collected over From enrollment until last safety call, on day 49 (+/- 5 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gaboxadol in Home0/10 (0%)0/10 (0%)2/10 (20%)
Gaboxadol in Lab0/10 (0%)0/10 (0%)5/10 (50%)
Placebo in Home0/10 (0%)0/10 (0%)0/10 (0%)
Placebo in Lab0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Most frequent other events
EventGaboxadol in HomeGaboxadol in LabPlacebo in HomePlacebo in Lab
FatigueGeneral disorders2/104/100/101/10
FeverGeneral disorders0/101/100/100/10
Elevated heart rateCardiac disorders0/100/100/101/10
Emotional disturbance (anxiety, aggression, crying)Psychiatric disorders0/100/100/101/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in HomeTotal
<=18 years00000
Between 18 and 65 years233210
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in HomeTotal
Female00000
Male233210
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in HomeTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White233210
More than one race00000
Unknown or Not Reported00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo in Lab, Gaboxadol in Home, Gaboxadol in Lab, Placebo in HomeGaboxadol in Lab, Gaboxadol in Home, Placebo in Lab, Placebo in HomePlacebo in Lab, Placebo in Home, Gaboxadol in Lab, Gaboxadol in HomeGaboxadol in Lab, Placebo in Home, Placebo in Lab, Gaboxadol in HomeTotal
Hispanic or Latino10102
Not Hispanic or Latino13228
Unknown or Not Reported00000
08

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
09

References and documents

Publications

  • De Stefano LA, Kim H, Erickson CA, Schmitt LM, Dominick KC, Pedapati EV, Huckle R, Wilson R, McKinney WS, Reisinger DL, Nelson MN, Dapore AE, Horn PS, Miyakoshi M. Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting. J Neurodev Disord. 2026 May 8;18(1):36. doi: 10.1186/s11689-026-09700-5. PubMed 42104256 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in May 2025, 15 months.

Results were first posted in Sep 2026, 1 year 4 months after primary completion.

Of 15 phase 2 interventional studies under Fragile X Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 28, 2024
StartActual
Jan 29, 2024
Primary completionActual
May 13, 2025
CompletionActual
Jun 24, 2025
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Interventions
Arms added: Placebo in lab, Gaboxadol in home, Gaboxadol in lab, Placebo in home·Gaboxadol in lab, Gaboxadol in home, Placebo in lab, Placebo in home·Placebo in lab, Placebo in home, Gaboxadol in lab, Gaboxadol in home·Gaboxadol in lab, Placebo in home, Placebo in lab, Gaboxadol in home; arms removed: All Study Participants
Sep 30, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedTo evaluate target engagementTarget Engagement of gaboxadol treatmentGaboxadol Treatment on high density EEG recordingsPowerTime frame: Pre-dose, 60 minutes post-dose → Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
  • AddedTarget Engagement of Gaboxadol Treatment on Auditory ChirpTime frame: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Sep 30, 2026
Documents
Secondary outcomes
7 edited
What changed in the outcomes
  • EditedTo investigateInvestigate the feasibilityFeasibility of home research visitsHome Research Visits and proceduresProcedures in adult males withAdult Males With FXSTime frame: Pre-dose, 60 minutes post-dose
  • EditedTo investigateInvestigate the feasibilityFeasibility of high densityHigh Density EEG recordingRecording at homeHome in adult males withAdult Males With FXSTime frame: Pre-dose, 60 minutes post-dose → Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42
  • EditedTo potentially explorePotentially Explore the pharmacokineticsPharmacokinetics of gaboxadol treatmentGaboxadol Treatment in singleSingle-dose trial designTrial DesignTime frame: Pre-dose, 60 minutes post-dose → Sixty minutes post-dose on 4 study visits, up to day 42
  • EditedTo investigateInvestigate the effectEffect of gaboxadol treatmentGaboxadol Treatment on neuropsychological assessmentsNeuropsychological AssessmentsTime frame: Pre-dose, 60 minutes post-dose → Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
  • EditedTo investigateInvestigate the effectEffect of gaboxadol treatmentGaboxadol Treatment on eye tracking assessmentsEye Tracking AssessmentsTime frame: Pre-dose, 60 minutes post-dose → Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
  • EditedTo investigateInvestigate the effectEffect of gaboxadol treatmentGaboxadol Treatment on clinicianClinician-rated measuresMeasuresTime frame: Pre-dose and post-dose → Post-dose on 4 study visits, up to day 42
  • EditedTo determine whetherDetermine Whether FMRP levels predict treatment responseLevels Predict Treatment ResponseTime frame: Pre-dose and post-dose → Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedTo evaluate target engagementTarget Engagement of gaboxadol treatmentGaboxadol Treatment on high density EEG recordingsPowerTime frame: Pre-dose, 60 minutes post-dose → Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
    • AddedTarget Engagement of Gaboxadol Treatment on Auditory ChirpTime frame: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
    Secondary outcomes 7 edited
    What changed in the outcomes
    • EditedTo investigateInvestigate the feasibilityFeasibility of home research visitsHome Research Visits and proceduresProcedures in adult males withAdult Males With FXSTime frame: Pre-dose, 60 minutes post-dose
    • EditedTo investigateInvestigate the feasibilityFeasibility of high densityHigh Density EEG recordingRecording at homeHome in adult males withAdult Males With FXSTime frame: Pre-dose, 60 minutes post-dose → Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42
    • EditedTo potentially explorePotentially Explore the pharmacokineticsPharmacokinetics of gaboxadol treatmentGaboxadol Treatment in singleSingle-dose trial designTrial DesignTime frame: Pre-dose, 60 minutes post-dose → Sixty minutes post-dose on 4 study visits, up to day 42
    • EditedTo investigateInvestigate the effectEffect of gaboxadol treatmentGaboxadol Treatment on neuropsychological assessmentsNeuropsychological AssessmentsTime frame: Pre-dose, 60 minutes post-dose → Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
    • EditedTo investigateInvestigate the effectEffect of gaboxadol treatmentGaboxadol Treatment on eye tracking assessmentsEye Tracking AssessmentsTime frame: Pre-dose, 60 minutes post-dose → Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
    • EditedTo investigateInvestigate the effectEffect of gaboxadol treatmentGaboxadol Treatment on clinicianClinician-rated measuresMeasuresTime frame: Pre-dose and post-dose → Post-dose on 4 study visits, up to day 42
    • EditedTo determine whetherDetermine Whether FMRP levels predict treatment responseLevels Predict Treatment ResponseTime frame: Pre-dose and post-dose → Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
    Interventions Arms added: Placebo in lab, Gaboxadol in home, Gaboxadol in lab, Placebo in home·Gaboxadol in lab, Gaboxadol in home, Placebo in lab, Placebo in home·Placebo in lab, Placebo in home, Gaboxadol in lab, Gaboxadol in home·Gaboxadol in lab, Placebo in home, Placebo in lab, Gaboxadol in home; arms removed: All Study Participants
    + 3 other changes: verification date, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06334419
Lead sponsor
Craig Erickson
Collaborators
Healx Limited
Responsible party
Craig Erickson (Research Director and Research Endowed Professor, Children's Hospital Medical Center, Cincinnati) — Sponsor-investigator
First posted
Mar 28, 2024
Start date
Jan 29, 2024
Primary completion
May 13, 2025
Completion
Jun 24, 2025
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Cragi A Erickson, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gaboxadol

Start the discussion